U
Advanced Proteome Therapeutics Corporation
APTCF
$0.0002
-$0.0365-99.46%
E
Sell
8/25/2023Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to E+ from D- on 8/25/2023 due to a decline in the total return index and volatility index.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to E+ from D- on 8/25/2023 due to a decline in the total return index and volatility index.
D
Sell
5/26/2023Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D- from E+ on 5/26/2023 due to an increase in the volatility index.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D- from E+ on 5/26/2023 due to an increase in the volatility index.
E
Sell
4/6/2023Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to E+ from D- on 4/6/2023 due to a decline in the valuation index, volatility index and solvency index. Debt to equity increased from 0.55 to 1.09, and the quick ratio declined from 0.3 to 0.24.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to E+ from D- on 4/6/2023 due to a decline in the valuation index, volatility index and solvency index. Debt to equity increased from 0.55 to 1.09, and the quick ratio declined from 0.3 to 0.24.
D
Sell
3/14/2023Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
D
Sell
2/9/2023Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D from E+ on 02/09/2023.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index.
D
Sell
2/2/2023Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from D on 2/2/2023 due to a decline in the total return index.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from D on 2/2/2023 due to a decline in the total return index.
D
Sell
1/6/2023Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D from D- on 1/6/2023 due to an increase in the total return index and volatility index.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D from D- on 1/6/2023 due to an increase in the total return index and volatility index.
D
Sell
12/22/2022Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from D+ on 12/22/2022 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from -$0.0019 to -$0.0053, net income declined 175.2% from -$76.2 to -$209.7, and total capital declined 57.32% from -$338.1 to -$531.9.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from D+ on 12/22/2022 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from -$0.0019 to -$0.0053, net income declined 175.2% from -$76.2 to -$209.7, and total capital declined 57.32% from -$338.1 to -$531.9.
D
Sell
12/7/2022Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D+ from C- on 12/7/2022 due to a decline in the volatility index.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D+ from C- on 12/7/2022 due to a decline in the volatility index.
C
Hold
11/22/2022Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to C- from D+ on 11/22/2022 due to a large increase in the growth index, solvency index and total return index. Earnings per share increased from -$0.0118 to -$0.0019, and debt to equity declined from 1.1 to 0.48.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to C- from D+ on 11/22/2022 due to a large increase in the growth index, solvency index and total return index. Earnings per share increased from -$0.0118 to -$0.0019, and debt to equity declined from 1.1 to 0.48.
D
Sell
6/29/2022Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D+ from D on 6/29/2022 due to a significant increase in the valuation index and efficiency index.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D+ from D on 6/29/2022 due to a significant increase in the valuation index and efficiency index.
D
Sell
5/5/2022Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D from D- on 05/05/2022.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D from D- on 05/05/2022.
D
Sell
4/20/2022Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the total return index and volatility index.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the total return index and volatility index.
D
Sell
11/23/2021Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D from D- on 11/23/2021.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D from D- on 11/23/2021.
D
Sell
11/8/2021Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from D on 11/8/2021 due to a decline in the total return index and volatility index.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from D on 11/8/2021 due to a decline in the total return index and volatility index.
D
Sell
8/3/2021Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D from D+ on 8/3/2021 due to a noticeable decline in the total return index.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D from D+ on 8/3/2021 due to a noticeable decline in the total return index.
D
Sell
6/30/2021Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D+ from D on 6/30/2021 due to a significant increase in the total return index, volatility index and solvency index. The quick ratio increased from 0.01 to 0.97, and debt to equity declined from 2.33 to -0.32.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D+ from D on 6/30/2021 due to a significant increase in the total return index, volatility index and solvency index. The quick ratio increased from 0.01 to 0.97, and debt to equity declined from 2.33 to -0.32.
D
Sell
7/6/2020Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D from D- on 7/6/2020 due to a noticeable increase in the growth index, total return index and solvency index. The quick ratio increased from 0.02 to 0.07, and EBIT increased 0.15% from -$135.8 to -$135.6.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D from D- on 7/6/2020 due to a noticeable increase in the growth index, total return index and solvency index. The quick ratio increased from 0.02 to 0.07, and EBIT increased 0.15% from -$135.8 to -$135.6.
D
Sell
5/1/2020Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from D on 5/1/2020 due to a significant decline in the efficiency index, growth index and solvency index. Earnings per share declined from -$0.0008 to -$0.0054, net income declined 539.33% from -$17.8 to -$113.8, and debt to equity increased from 0.56 to 0.85.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from D on 5/1/2020 due to a significant decline in the efficiency index, growth index and solvency index. Earnings per share declined from -$0.0008 to -$0.0054, net income declined 539.33% from -$17.8 to -$113.8, and debt to equity increased from 0.56 to 0.85.
D
Sell
1/8/2020Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D from D+ on 1/8/2020 due to a decline in the total return index and volatility index.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D from D+ on 1/8/2020 due to a decline in the total return index and volatility index.
D
Sell
12/24/2019Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D+ from D on 12/24/2019 due to a noticeable increase in the growth index. Earnings per share increased from -$0.0111 to -$0.0008, EBIT increased 59.22% from -$284.2 to -$115.9, and operating cash flow increased 53.39% from -$216.7 to -$101.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D+ from D on 12/24/2019 due to a noticeable increase in the growth index. Earnings per share increased from -$0.0111 to -$0.0008, EBIT increased 59.22% from -$284.2 to -$115.9, and operating cash flow increased 53.39% from -$216.7 to -$101.
D
Sell
11/29/2019Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D from D+ on 11/29/2019 due to a decline in the growth index and volatility index. Earnings per share declined from -$0.0023 to -$0.0117, EBIT declined 78.74% from -$159 to -$284.2, and operating cash flow declined 34.6% from -$161 to -$216.7.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D from D+ on 11/29/2019 due to a decline in the growth index and volatility index. Earnings per share declined from -$0.0023 to -$0.0117, EBIT declined 78.74% from -$159 to -$284.2, and operating cash flow declined 34.6% from -$161 to -$216.7.
D
Sell
9/23/2019Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D+ from D on 9/23/2019 due to an increase in the volatility index, valuation index and efficiency index. Total capital increased 11.68% from -$679.2 to -$599.9.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D+ from D on 9/23/2019 due to an increase in the volatility index, valuation index and efficiency index. Total capital increased 11.68% from -$679.2 to -$599.9.
D
Sell
5/17/2019Downgrade
Advanced Proteome Therapeutics Corporation (APTCD) was downgraded to D from D+ on 5/17/2019 due to a decline in the total return index and volatility index.
Advanced Proteome Therapeutics Corporation (APTCD) was downgraded to D from D+ on 5/17/2019 due to a decline in the total return index and volatility index.
D
Sell
5/2/2019Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D+ from D on 5/2/2019 due to an increase in the total return index.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D+ from D on 5/2/2019 due to an increase in the total return index.
D
Sell
4/17/2019Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D from D+ on 4/17/2019 due to a large decline in the total return index, volatility index and solvency index. The quick ratio declined from 0.24 to 0.07.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D from D+ on 4/17/2019 due to a large decline in the total return index, volatility index and solvency index. The quick ratio declined from 0.24 to 0.07.
D
Sell
11/26/2018Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D+ from C- on 11/26/2018 due to a decline in the total return index and volatility index.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D+ from C- on 11/26/2018 due to a decline in the total return index and volatility index.
C
Hold
9/20/2018Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to C- from D+ on 9/20/2018 due to a noticeable increase in the total return index and volatility index.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to C- from D+ on 9/20/2018 due to a noticeable increase in the total return index and volatility index.
D
Sell
7/23/2018Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D+ from C- on 7/23/2018 due to a noticeable decline in the total return index, volatility index and solvency index.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D+ from C- on 7/23/2018 due to a noticeable decline in the total return index, volatility index and solvency index.
C
Hold
6/29/2018Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to C- from D+ on 6/29/2018 due to a noticeable increase in the growth index, solvency index and total return index. The quick ratio increased from 0.06 to 0.56, earnings per share increased from -$0.0044 to $0.0029, and debt to equity declined from 0.92 to 0.05.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to C- from D+ on 6/29/2018 due to a noticeable increase in the growth index, solvency index and total return index. The quick ratio increased from 0.06 to 0.56, earnings per share increased from -$0.0044 to $0.0029, and debt to equity declined from 0.92 to 0.05.
D
Sell
6/8/2018Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D+ from D on 6/8/2018 due to an increase in the volatility index.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D+ from D on 6/8/2018 due to an increase in the volatility index.
D
Sell
5/11/2018Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D from D+ on 5/11/2018 due to a decline in the solvency index and volatility index.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D from D+ on 5/11/2018 due to a decline in the solvency index and volatility index.
D
Sell
4/2/2018Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D+ from D on 4/2/2018 due to a significant increase in the efficiency index and total return index.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D+ from D on 4/2/2018 due to a significant increase in the efficiency index and total return index.
D
Sell
7/28/2017Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D from D- on 7/28/2017 due to an increase in the volatility index and total return index.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D from D- on 7/28/2017 due to an increase in the volatility index and total return index.
D
Sell
6/30/2017Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from D on 6/30/2017 due to a noticeable decline in the growth index, valuation index and solvency index. Debt to equity increased from 0.18 to 0.38, the quick ratio declined from 0.13 to 0.09, and EBIT declined 21.11% from -$248.7 to -$301.2.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from D on 6/30/2017 due to a noticeable decline in the growth index, valuation index and solvency index. Debt to equity increased from 0.18 to 0.38, the quick ratio declined from 0.13 to 0.09, and EBIT declined 21.11% from -$248.7 to -$301.2.
D
Sell
12/12/2016Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D from D- on 12/12/2016 due to an increase in the valuation index and growth index.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D from D- on 12/12/2016 due to an increase in the valuation index and growth index.
D
Sell
10/20/2016Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from D on 10/20/2016 due to a decline in the total return index and volatility index.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from D on 10/20/2016 due to a decline in the total return index and volatility index.
D
Sell
10/5/2016Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D from D- on 10/5/2016 due to an increase in the volatility index.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D from D- on 10/5/2016 due to an increase in the volatility index.
D
Sell
8/29/2016Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from D on 8/29/2016 due to a decline in the total return index.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from D on 8/29/2016 due to a decline in the total return index.
D
Sell
7/27/2016Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D from D- on 7/27/2016 due to an increase in the total return index, volatility index and solvency index.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D from D- on 7/27/2016 due to an increase in the total return index, volatility index and solvency index.
D
Sell
6/29/2016Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from D on 6/29/2016 due to a noticeable decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.11 to 0.12.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from D on 6/29/2016 due to a noticeable decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.11 to 0.12.
D
Sell
3/14/2016Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D from D+ on 3/14/2016 due to a major decline in the volatility index and total return index.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D from D+ on 3/14/2016 due to a major decline in the volatility index and total return index.
D
Sell
2/26/2016Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D+ from D on 2/26/2016 due to an increase in the valuation index.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D+ from D on 2/26/2016 due to an increase in the valuation index.
D
Sell
12/29/2015Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D from D+ on 12/29/2015 due to a decline in the total return index, solvency index and valuation index. The quick ratio declined from 1.27 to 0.95, and debt to equity increased from 0.09 to 0.1.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D from D+ on 12/29/2015 due to a decline in the total return index, solvency index and valuation index. The quick ratio declined from 1.27 to 0.95, and debt to equity increased from 0.09 to 0.1.
D
Sell
12/10/2015Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D+ from D on 12/10/2015 due to a noticeable increase in the growth index.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D+ from D on 12/10/2015 due to a noticeable increase in the growth index.
D
Sell
12/2/2015Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D from D- on 12/2/2015 due to an increase in the growth index and valuation index. Earnings per share increased from -$0.0029 to -$0.0039, and EBIT increased 19.78% from -$249.7 to -$299.1.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to D from D- on 12/2/2015 due to an increase in the growth index and valuation index. Earnings per share increased from -$0.0029 to -$0.0039, and EBIT increased 19.78% from -$249.7 to -$299.1.
D
Sell
6/30/2015Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from C- on 6/30/2015 due to a significant decline in the efficiency index, valuation index and growth index. Total capital declined 29.95% from $240.1 to $168.2, and EBIT declined 14.63% from -$292.5 to -$249.7.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D- from C- on 6/30/2015 due to a significant decline in the efficiency index, valuation index and growth index. Total capital declined 29.95% from $240.1 to $168.2, and EBIT declined 14.63% from -$292.5 to -$249.7.
C
Hold
5/6/2015Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to C- from C on 5/6/2015 due to a decline in the total return index and valuation index.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to C- from C on 5/6/2015 due to a decline in the total return index and valuation index.
C
Hold
4/17/2015Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to C from C+ on 4/17/2015 due to a substantial decline in the valuation index, total return index and volatility index.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to C from C+ on 4/17/2015 due to a substantial decline in the valuation index, total return index and volatility index.
C
Hold
4/2/2015Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to C+ from D on 4/2/2015 due to a significant increase in the efficiency index, valuation index and volatility index. Net income increased 66.28% from -$128.7 to -$214.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to C+ from D on 4/2/2015 due to a significant increase in the efficiency index, valuation index and volatility index. Net income increased 66.28% from -$128.7 to -$214.
D
Sell
12/26/2014Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D from C- on 12/26/2014 due to a significant decline in the efficiency index and growth index. Total capital declined 269.96% from -$260.3 to $442.4, net income declined 131.9% from $403.4 to -$128.7, and earnings per share declined from $0.0039 to -$0.0012.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D from C- on 12/26/2014 due to a significant decline in the efficiency index and growth index. Total capital declined 269.96% from -$260.3 to $442.4, net income declined 131.9% from $403.4 to -$128.7, and earnings per share declined from $0.0039 to -$0.0012.
C
Hold
11/26/2014Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to C- from D+ on 11/26/2014 due to a significant increase in the efficiency index, solvency index and growth index. Debt to equity declined from -0.5 to 0.26, net income increased 112.2% from $190.1 to $403.4, and earnings per share increased from $0.0019 to $0.0039.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to C- from D+ on 11/26/2014 due to a significant increase in the efficiency index, solvency index and growth index. Debt to equity declined from -0.5 to 0.26, net income increased 112.2% from $190.1 to $403.4, and earnings per share increased from $0.0019 to $0.0039.
D
Sell
10/27/2014Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D+ from C- on 10/27/2014 due to a decline in the volatility index and total return index.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D+ from C- on 10/27/2014 due to a decline in the volatility index and total return index.
C
Hold
10/10/2014Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to C- from D+ on 10/10/2014 due to an increase in the volatility index, total return index and valuation index.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to C- from D+ on 10/10/2014 due to an increase in the volatility index, total return index and valuation index.
D
Sell
9/25/2014Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D+ from C- on 9/25/2014 due to a significant decline in the volatility index.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to D+ from C- on 9/25/2014 due to a significant decline in the volatility index.
C
Hold
7/7/2014Downgrade
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to C- from C on 7/7/2014 due to a significant decline in the efficiency index, total return index and solvency index. Debt to equity increased from -0.14 to -0.5, net income declined 111.41% from -$1.67M to $190.1, and total capital declined 42.45% from -$1.85M to -$1.06M.
Advanced Proteome Therapeutics Corporation (APTCF) was downgraded to C- from C on 7/7/2014 due to a significant decline in the efficiency index, total return index and solvency index. Debt to equity increased from -0.14 to -0.5, net income declined 111.41% from -$1.67M to $190.1, and total capital declined 42.45% from -$1.85M to -$1.06M.
C
Hold
4/11/2014Upgraded
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to C from D+ on 4/11/2014 due to a significant increase in the efficiency index, valuation index and total return index. Net income increased 2,058.42% from -$77.2 to -$1.67M, and total capital increased 259.07% from -$514.8 to -$1.85M.
Advanced Proteome Therapeutics Corporation (APTCF) was upgraded to C from D+ on 4/11/2014 due to a significant increase in the efficiency index, valuation index and total return index. Net income increased 2,058.42% from -$77.2 to -$1.67M, and total capital increased 259.07% from -$514.8 to -$1.85M.
OTC PK
07/28/2023 1:55PM Eastern
Quotes delayed
